Ophthalmology · GlaucomaRegulatory Approvalcommercialnear-term

FDA Grants AP Status for Brimonidine Tartrate ANDA216772

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 12:32:05 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated Approval for Upsher Smith Labs' generic Brimonidine Tartrate is significant as it introduces a new competitor in the glaucoma treatment market. This could lead to pricing pressures and shifts in market share for existing branded products, necessitating close monitoring by portfolio teams. Regulatory context from FDA (FDA AP — BRIMONIDINE TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 11 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this generic entry on pricing and market share for existing branded products in the glaucoma category. The strongest clinical anchor is RSV Immunisation Status in Queensland (Australia) (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In ophthalmology, 8 regulatory and 2 competitive items passed relevance filtering for Upsher Smith Labs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease (Humanexa Signals) — sub-indication match (ophthalmology); sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease. This approval allows Upsher Smith Labs to enter the market with a generic version of Brimonidine Tartrate, potentially increasing competition in the glaucoma treatment space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BRIMONIDINE TARTRATE (SUPPL) (FDA). Entity match (upsher smith labs); Regulatory pathway relevance (nda). The approval itself does not pose immediate regulatory concerns but indicates a shift in market competition that may require strategic adjustments.

Key Opportunities

The entry of a generic competitor may reduce prices and impact revenue for existing branded products in the glaucoma category, affecting overall market dynamics.
Portfolio teams should assess the impact of this generic entry on pricing and market share for existing branded products in the glaucoma category.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market uptake of Upsher Smith's Brimonidine Tartrate to gauge competitive dynamics.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (upsher smith labs); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source

RSV Immunisation Status in Queensland (Australia)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of Feeding Status on Appetite and Eating Behaviour.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Can Vitamin D Replacement Correct Chronic Disease Anemia?
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Project VIBE: Virtual Intervention for Binge Eating in Adolescents
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Non-Invasive Median Nerve Stimulation to Attenuate Atrial Tachyarrhythmias After Catheter Ablation for Atrial Fibrillation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease
Humanexa Signalshigh relevance
Sub-indication match (ophthalmology); Sponsor/company relevance (Roche)
FDA Grants Priority Review for Roche's Enspryng in Thyroid Eye Disease
Humanexa Signalshigh relevance
Sub-indication match (ophthalmology); Sponsor/company relevance (Roche)
FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Baseline microperimetry and metabolic status predict functional outcomes in diabetic macular oedema: a prospective cohort study of anti-VEGF therapy.
PubMedhigh relevance
Sub-indication match (ophthalmology)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Upsher Smith Labs
Brimonidine Tartrate
glaucoma treatment market

Commercial impact

medium

The entry of a generic competitor may reduce prices and impact revenue for existing branded products in the glaucoma category, affecting overall market dynamics.

Regulatory impact

low

The approval itself does not pose immediate regulatory concerns but indicates a shift in market competition that may require strategic adjustments.

What to watch

Monitor the launch timeline and market uptake of Upsher Smith's Brimonidine Tartrate to gauge competitive dynamics.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.